1 October 2024 Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer read more
26 September 2024 ReCode Therapeutics Doses First Patient in Phase 1b Clinical Study of RCT2100 for the Treatment of Cystic Fibrosis read more
9 September 2024 Candid Therapeutics Debuts with $370M Capital Raise to Clinically Evaluate Potentially Transformative Autoimmune Therapies read more
12 August 2024 Halda Therapeutics Secures $126 Million Financing to Advance RIPTAC™ Cancer Therapies into the Clinic for Major Solid Tumors read more
